Anatara Lifesciences

ANR.AX

Biotechnology · Healthcare

Price

A$0.01

+0.00 (+0.00%)

Market Cap

A$2.1M

Exchange

Australian Securities Exchange

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Based on the IPO prospectus (annual filing). This score will refine automatically once the company reports its first quarters.

Data as of Jul 28, 2026 · filings through Dec 31, 2025

Share count rising — dilution

+196.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 69.0M (2021) → 204.7M (2025)

Anatara Lifesciences is a small Australian biotechnology company focused on developing treatments for gut health problems. Its main work centers on gastrointestinal diseases, including a product called Detach aimed at reducing gut damage in cancer patients undergoing treatment. The company targets medical conditions where there are few good treatment options, working toward getting its drugs approved for use by patients and doctors.

Anatara makes no meaningful revenue yet and operates at a significant loss, which is typical for early-stage drug developers. It is based in Australia and is a very small company, with most of its funding coming from share issuances rather than product sales. The biggest risk the company faces is the uncertainty of clinical trials — if its drug candidates fail to prove safe and effective in testing, the company could run out of money before reaching the market.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+181.8% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+57.8% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$2M/ year

↑ Rising (+114% vs prior year)

165.4% of revenue

9.2x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

26.6%ownership

Insiders own a meaningful stake in the company

Cash Runway

~0 months

$101,356 cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Revenue accelerating

Anatara Lifesciences grew revenue 182% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

-65.4%

Thin — -65.4% gross margin

Operating Margin

-201.8%

Losing money on operations — -201.8%

ROCE

-207.4%

Weak — -207.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+50.5%

Fast-growing sales (50.5% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-234.4%

Burning cash (-234.4%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.76

Moderate — manageable debt (0.76)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial